EP Patent

EP3077390B1 — Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist

Assigned to Idorsia Pharmaceuticals Ltd · Expires 2017-09-13 · 9y expired

What this patent protects

Patent listed against daridorexant-hydrochloride.

Drugs covered by this patent

daridorexant-hydrochloride (DARIDOREXANT HYDROCHLORIDE)

Patent Metadata

Patent number: EP3077390B1
Jurisdiction: EP
Classification: —
Expires: 2017-09-13
Drug substance claim: No
Drug product claim: No
Assignee: Idorsia Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.